The US medical cannabis industry has entered 2026 with robust momentum, according to the latest quarterly analysis from industry research firms BDSA and MJBiz. The Q1 2026 report, released on 15 March 2026, projects that the total legal cannabis market—combining medical and adult-use sales—will exceed $45 billion by 2027, driven by sustained patient enrolment, new state-level expansions, and maturing supply chains. However, the report also highlights significant headwinds, including price compression in mature markets and uneven performance among multi-state operators.
Record Revenues and Revised Projections
The first quarter of 2026 saw US medical cannabis sales reach an estimated $8.2 billion, a 12% increase year-on-year. BDSA analysts attribute this growth to the continued rollout of telehealth renewals and the inclusion of chronic pain as a qualifying condition in states such as Florida and Pennsylvania. MJBiz has revised its 2027 market forecast upward from $42 billion to $45.8 billion, citing stronger-than-expected demand in the Midwest and Northeast. ‘We are seeing a structural shift in patient demographics,’ said Dr Eleanor Vance, chief analyst at BDSA, during a 20 March webinar. ‘Older adults, particularly those over 65, now represent 38% of medical cannabis registrations, up from 28% in 2023.’ This demographic trend is bolstering sales of tinctures, topicals, and low-THC edibles, which command higher margins than flower.
Multi-State Operators Face Margin Squeeze
While the headline figures are encouraging, the Q1 2026 data reveals a split market. Established multi-state operators (MSOs) such as Curaleaf, Trulieve, and Green Thumb Industries reported average wholesale flower prices falling by 18% year-on-year in mature markets like Colorado, Oregon, and Washington. In these states, oversupply and aggressive discounting have compressed gross margins to below 40% for some cultivators. ‘The price compression in the West is brutal,’ noted Michael Torres, CEO of a Colorado-based cultivation collective, in a 2 April interview with MJBiz. ‘We are seeing flower selling for as little as $600 per pound, down from $1,200 two years ago.’ To offset this, MSOs are pivoting to value-added products and proprietary genetics, while also lobbying for federal reform. The SAFE Banking Act 2.0, reintroduced on 10 January 2026 as H.R. 289, has gained bipartisan co-sponsors but remains stalled in the Senate Banking Committee. Industry groups argue that access to traditional banking would alleviate capital costs and stabilise pricing.
Emerging Markets and Regulatory Tailwinds
In contrast to the West, emerging markets in the South and Midwest offer a brighter picture. Texas, which expanded its compassionate use programme in late 2025, saw medical cannabis sales jump 45% quarter-on-quarter, albeit from a low base. Similarly, Kentucky’s new medical cannabis programme, signed into law in March 2024 and fully operational by January 2026, has already registered over 50,000 patients. Governor Andy Beshear’s office confirmed on 28 March that the state expects to issue 200 dispensary licences by June 2026. Federal-level developments also provide cautious optimism. The Drug Enforcement Administration’s ongoing review of cannabis rescheduling, initiated in August 2023, has entered a new phase with public hearings scheduled for May 2026. If cannabis is moved from Schedule I to Schedule III, medical cannabis businesses could deduct ordinary business expenses under Section 280E of the tax code, potentially saving the industry billions annually. ‘Rescheduling would be a game-changer for margins,’ said MJBiz analyst Sarah Kim in the Q1 report. ‘But we are not holding our breath—politics remains the wild card.’ For now, the industry continues to grow, albeit with a clear divide between the bustling frontiers and the price-squeezed heartlands.
